Who are the subjects for the 64Cu-PSMA-I&T trial?

Initial Japanese prostate cancer patients with intermediate to very high risk, scheduled for surgery.

What is Curium's role in the development?

Curium leads overseas development and transfers high-throughput 64Cu manufacturing technology to PDR Pharma.

What is the next step?

Combining this trial's results with overseas data to file for domestic manufacturing and marketing approval.

AI News NQ Analysis

PeptiDream, PDR Pharma, and Curium Complete Patient Administration in Domestic Clinical Trial for Prostate Cancer Diagnostic Candidate 64Cu-PSMA-I&T

NQ Score 82/100

N1 Content Completeness 9

Key facts

PeptiDream, PDR Pharma, and Curium Complete Patient Administration in Domestic Clinical Trial for Prostate Cancer Diagnostic Candidate 64Cu-PSMA-I&T
PeptiDream, PDR Pharma, and Curium announced the completion of patient administration in a domestic clinical trial aiming for the approval of the PET diagnostic candidate 64Cu-PSMA-I&T for prostate cancer. Results will support the regulatory filing along with overseas data.
Source: PR TIMES
Date: Fri Jun 12 2026 01:22:10 GMT+0900 (Japan Standard Time)

Direct answer

PeptiDream, PDR Pharma, and Curium announced the completion of patient administration in a domestic clinical trial aiming for the approval of the PET diagnostic candidate 64Cu-PSMA-I&T for prostate cancer. Results will support the regulatory filing along with overseas data.

Citation: PeptiDream, PDR Pharma, and Curium Complete Patient Administration in Domestic Clinical Trial for Prostate Cancer Diagnostic Candidate 64Cu-PSMA-I&T (Fri Jun 12 2026 01:22:10 GMT+0900 (Japan Standard Time)), PR TIMES
Source: PR TIMES
Date: Fri Jun 12 2026 01:22:10 GMT+0900 (Japan Standard Time)

AI Summary (NQ-processed)

PeptiDream, PDR Pharma, and Curium announced the completion of patient administration in a domestic clinical trial aiming for the approval of the PET diagnostic candidate 64Cu-PSMA-I&T for prostate cancer. Results will support the regulatory filing along with overseas data.

AI Analysis

Frequently Asked Questions

Q: Who are the subjects for the 64Cu-PSMA-I&T trial?: A: Initial Japanese prostate cancer patients with intermediate to very high risk, scheduled for surgery.
Q: What is Curium's role in the development?: A: Curium leads overseas development and transfers high-throughput 64Cu manufacturing technology to PDR Pharma.
Q: What is the next step?: A: Combining this trial's results with overseas data to file for domestic manufacturing and marketing approval.